EcoDrugPlus

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSPNYG00000015172
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPNYG00000009353
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPNYG00000009930
Gene Symbol: RAMP1
3 Cross references
191 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSPNYG00000014044
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSPNYG00000018276
Gene Symbol: LOC102199268
3 Cross references
203 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSPNYG00000002978
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSPNYG00000004000
Gene Symbol: RET
3 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSPNYG00000019132
Gene Symbol: LOC102210873
3 Cross references
225 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSPNYG00000013852
Gene Symbol: LOC102210745
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSPNYG00000015809
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSPNYG00000001016
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSPNYG00000021740
Gene Symbol: LOC102205684
2 Cross references
380 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).